|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2001-3-6
|
|
pubmed:abstractText |
Exposure of RPMI 8226, Karpas 707 and U266 human myeloma-like lines to low doses of As(2)O(3) was followed by a marked increase in lymphokine activated killers (LAK)-mediated killing and up- modulation of CD38 and CD54, two molecules involved in cell-cell interactions. Moreover, simultaneous exposure of effectors and targets to As(2)O(3) yielded the most effective condition for lysis. The expression of CD31 (CD38 ligand) and CD11a (CD54 ligand) was also up-regulated by LAK, suggesting that increased adhesion was responsible for the improved killing. Similar results were obtained using freshly isolated myeloma cells. These findings indicate that As(2)O(3) may be useful to boost the immune system against myelomas.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/ADP-ribosyl Cyclase,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD38,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Arsenicals,
http://linkedlifedata.com/resource/pubmed/chemical/CD38 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Growth Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Intercellular Adhesion Molecule-1,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/NAD Nucleosidase,
http://linkedlifedata.com/resource/pubmed/chemical/Oxides,
http://linkedlifedata.com/resource/pubmed/chemical/arsenic trioxide
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0145-2126
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
227-35
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11226519-ADP-ribosyl Cyclase,
pubmed-meshheading:11226519-Antigens, CD,
pubmed-meshheading:11226519-Antigens, CD38,
pubmed-meshheading:11226519-Antigens, Differentiation,
pubmed-meshheading:11226519-Antineoplastic Agents,
pubmed-meshheading:11226519-Arsenicals,
pubmed-meshheading:11226519-Cytotoxicity, Immunologic,
pubmed-meshheading:11226519-Dose-Response Relationship, Drug,
pubmed-meshheading:11226519-Growth Inhibitors,
pubmed-meshheading:11226519-Humans,
pubmed-meshheading:11226519-Immunophenotyping,
pubmed-meshheading:11226519-Intercellular Adhesion Molecule-1,
pubmed-meshheading:11226519-Killer Cells, Lymphokine-Activated,
pubmed-meshheading:11226519-Membrane Glycoproteins,
pubmed-meshheading:11226519-Multiple Myeloma,
pubmed-meshheading:11226519-NAD+ Nucleosidase,
pubmed-meshheading:11226519-Oxides,
pubmed-meshheading:11226519-Tumor Cells, Cultured
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells.
|
|
pubmed:affiliation |
Laboratory of Cell Biology, Department of Biology, Genetics and Biochemistry, University of Torino Medical School, via Santena 19, 10126 Torino, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
